STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient 

Bionpharma announced Wednesday the FDA approval of its etravirine tablets, an HIV therapy developed in partnership with STEERLife. The therapy was developed using STEERLife’s proprietary FragMelt continuous processing platform, which enables a sustainable, solvent-free manufacturing process.  Precise control: how FragMelt works with heat-sensitive drugs Etravirine is extremely sensitive to heat and shear forces, meaning traditional… The post STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient  appeared first on Drug Discovery and Development.

Continue reading →